Browse EV MemProt Atlas
Supporting publications (n)
Number of publications supporting the inclusion of this protein in EV MemProt Atlas.
EVMP confidence score
Annotation confidence score; open for threshold definitions.
Extremely high >= 0.85High >= 0.70Medium >= 0.55Low >= 0.40| UniProt ID | Protein names | Protein classification | Transmembrane count | Related Diseases | Mediation categories | Download | ||||
|---|---|---|---|---|---|---|---|---|---|---|
| FCRL6 | Q6DN72 | Fc receptor-like protein 6 (FcR-like protein 6) (FcRL6) (Fc receptor homolog 6) (FcRH6) (IFGP6) | 1 | Fusion and delivery mediation | 3 | 0.25 | ||||
| FRAS1 | Q86XX4 | Extracellular matrix organizing protein FRAS1 (Fraser syndrome 1 protein) | Disease related genesHuman disease related genesPredicted intracellular proteins | 1 | Other mediation | 3 | 0.25 | |||
| HLAB | P01889 | HLA class I histocompatibility antigen, B alpha chain (Human leukocyte antigen B) (HLA-B) | Cancer-related genesDisease related genesHuman disease related genes | 1 | Melanoma | Clinical-translation mediationFusion and delivery mediationImmune mediation | 3 | 0.25 | ||
| ITAL | P20701 | Integrin alpha-L (CD11 antigen-like family member A) (Leukocyte adhesion glycoprotein LFA-1 alpha chain) (LFA-1A) (Leukocyte function-associated molecule 1 alpha chain) (CD antigen CD11a) | CD markersFDA approved drug targetsPredicted intracellular proteins | 1 | Conjunctiva disorderDiabetes mellitusHuman immunodeficiency virus disease | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 3 | 0.25 | ||
| ITB6 | P18564 | Integrin beta-6 | Cancer-related genesDisease related genesHuman disease related genes | 1 | Solid tumour/cancer | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 3 | 0.25 | ||
| KI2L3 | P43628 | Killer cell immunoglobulin-like receptor 2DL3 (CD158 antigen-like family member B2) (KIR-023GB) (Killer inhibitory receptor cl 2-3) (NKAT2a) (NKAT2b) (Natural killer-associated transcript 2) (NKAT-2) (p58 natural killer cell receptor clone CL-6) (p58 NK receptor CL-6) (p58.2 MHC class-I-specific NK receptor) (CD antigen CD158b2) | 1 | Immune mediation | 3 | 0.25 | ||||
| LDLR | P01130 | Low-density lipoprotein receptor (LDL receptor) | Disease related genesHuman disease related genesMetabolic proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 3 | 0.25 | |||
| MXRA8 | Q9BRK3 | Matrix remodeling-associated protein 8 (Limitrin) | Predicted membrane proteins | 1 | Fusion and delivery mediationMetabolism mediation | 3 | 0.25 | |||
| NMUR1 | Q9HB89 | Neuromedin-U receptor 1 (NMU-R1) (G-protein coupled receptor 66) (G-protein coupled receptor FM-3) | G-protein coupled receptorsPredicted membrane proteinsTransporters | 7 | Fusion and delivery mediationReceptor-signaling mediation | 3 | 0.25 | |||
| OX2G | P41217 | OX-2 membrane glycoprotein (CD antigen CD200) | CD markersPredicted intracellular proteinsPredicted membrane proteins | 1 | Acute myeloid leukaemiaMature B-cell leukaemiaSolid tumour/cancer | Clinical-translation mediationFusion and delivery mediationImmune mediation | 3 | 0.25 | ||
| PARM1 | Q6UWI2 | Prostate androgen-regulated mucin-like protein 1 (PARM-1) | Predicted membrane proteins | 1 | Fusion and delivery mediation | 3 | 0.25 | |||
| PD1L2 | Q9BQ51 | Programmed cell death 1 ligand 2 (PD-1 ligand 2) (PD-L2) (PDCD1 ligand 2) (Programmed death ligand 2) (Butyrophilin B7-DC) (B7-DC) (CD antigen CD273) | Cancer-related genesCD markersPredicted membrane proteins | 1 | Adhesion and uptake mediationFusion and delivery mediationImmune mediation | 3 | 0.25 | |||
| SC6A2 | P23975 | Sodium-dependent noradrenaline transporter (Norepinephrine transporter) (NET) (Solute carrier family 6 member 2) | Disease related genesFDA approved drug targetsHuman disease related genes | 12 | Clinical-translation mediationFusion and delivery mediation | 3 | 0.25 | |||
| SUCR1 | Q9BXA5 | Succinate receptor 1 (G-protein coupled receptor 91) (P2Y purinoceptor 1-like) | G-protein coupled receptorsPredicted membrane proteins | 7 | Immune mediationMetabolism mediationReceptor-signaling mediation | 3 | 0.25 | |||
| TSHR | P16473 | Thyrotropin receptor (Thyroid-stimulating hormone receptor) (TSH-R) | Cancer-related genesDisease related genesFDA approved drug targets | 7 | Hypo-thyroidismThyroid cancer | Clinical-translation mediationMetabolism mediationReceptor-signaling mediation | 3 | 0.25 | ||
| TSN4 | O14817 | Tetraspanin-4 (Tspan-4) (Novel antigen 2) (NAG-2) (Transmembrane 4 superfamily member 7) | 4 | Adhesion and uptake mediation | 3 | 0.25 | ||||
| 5HT2B | P41595 | 5-hydroxytryptamine receptor 2B (5-HT-2B) (5-HT2B) (Serotonin receptor 2B) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Anxiety disorderAttention deficit hyperactivity disorderCoronary atherosclerosis | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.25 | ||
| ACE | P12821 | Angiotensin-converting enzyme (ACE) (EC 3.4.15.1) (Dipeptidyl carboxypeptidase I) (Kininase II) (CD antigen CD143) [Cleaved into: Angiotensin-converting enzyme, soluble form] | Candidate cardiovascular disease genesCD markersDisease related genes | 1 | AsthmaCardiovascular diseaseChronic kidney disease | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.25 | ||
| ADA2C | P18825 | Alpha-2C adrenergic receptor (Alpha-2 adrenergic receptor subtype C4) (Alpha-2C adrenoreceptor) (Alpha-2C adrenoceptor) (Alpha-2CAR) | FDA approved drug targetsG-protein coupled receptorsPredicted membrane proteins | 7 | Acute diabete complicationAlzheimer diseaseAsthma | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.25 | ||
| ANO9 | A1A5B4 | Anoctamin-9 (Transmembrane protein 16J) (Tumor protein p53-inducible protein 5) (p53-induced gene 5 protein) | Predicted membrane proteinsTransporters | 8 | Clinical-translation mediationFusion and delivery mediation | 2 | 0.25 | |||
| APJ | P35414 | Apelin receptor (Angiotensin receptor-like 1) (G-protein coupled receptor APJ) (G-protein coupled receptor HG11) | G-protein coupled receptorsPredicted membrane proteinsTransporters | 7 | Heart failure | Adhesion and uptake mediationClinical-translation mediationFusion and delivery mediation | 2 | 0.25 | ||
| AVR2A | P27037 | Activin receptor type-2A (EC 2.7.11.30) (Activin receptor type IIA) (ACTR-IIA) (ACTRIIA) | Cancer-related genesEnzymesPredicted membrane proteins | 1 | Acute myeloid leukaemiaIdiopathic inflammatory myopathyMuscle disorder | Clinical-translation mediationImmune mediationReceptor-signaling mediation | 2 | 0.25 | ||
| CADM2 | Q8N3J6 | Cell adhesion molecule 2 (Immunoglobulin superfamily member 4D) (IgSF4D) (Nectin-like protein 3) (NECL-3) (Synaptic cell adhesion molecule 2) (SynCAM 2) | Predicted membrane proteins | 1 | Adhesion and uptake mediationReceptor-signaling mediation | 2 | 0.25 | |||
| CC50A | Q9NV96 | Cell cycle control protein 50A (P4-ATPase flippase complex beta subunit TMEM30A) (Transmembrane protein 30A) | Predicted intracellular proteinsPredicted membrane proteinsTransporters | 2 | Clinical-translation mediationFusion and delivery mediationImmune mediation | 2 | 0.25 | |||
| CD244 | Q9BZW8 | Natural killer cell receptor 2B4 (NK cell activation-inducing ligand) (NAIL) (NK cell type I receptor protein 2B4) (NKR2B4) (h2B4) (SLAM family member 4) (SLAMF4) (Signaling lymphocytic activation molecule 4) (CD antigen CD244) | 1 | Fusion and delivery mediationImmune mediation | 2 | 0.25 |